Pamela L Wolters1, Staci Martin, Vanessa L Merker, Kathy L Gardner, Cynthia M Hingtgen, James H Tonsgard, Elizabeth K Schorry, Andrea Baldwin. 1. From the Pediatric Oncology Branch (P.L.W., S.M., A.B.), National Cancer Institute; Department of Neurology and Cancer Center (V.L.M.), Massachusetts General Hospital; Veterans Administration Pittsburgh Healthcare System and University of Pittsburgh (K.L.G.); Department of Clinical Neurosciences (C.M.H.), Spectrum Health Medical Group and College of Human Medicine, Michigan State University; University of Chicago Pritzker School of Medicine (J.H.T.); and Division of Human Genetics (E.K.S.), Cincinnati Children's Hospital.
Abstract
OBJECTIVES: Neurofibromatosis (NF) is a genetic disease with multiple clinical manifestations that can significantly impact quality of life (QOL). Clinical trials should include patient-reported outcomes (PROs) as endpoints to assess treatment effects on various aspects of QOL, but there is no consensus on the selection and use of such measures in NF. This article describes the PRO Working Group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Collaboration, its main goals, methods for identifying appropriate PRO measures for NF clinical trials, and recommendations for assessing pain intensity. METHODS: The REiNS PRO group selected core endpoint domains important to assess in NF. The members developed criteria to rate PRO measures, including patient characteristics, psychometric properties, and feasibility, and utilized a systematic process to evaluate PROs for NF clinical trials. Within the subdomain of pain intensity, the group reviewed the Numerical Rating Scale-11 (NRS-11), the Visual Analogue Scale, and the Faces Pain Scale-Revised using this process. RESULTS: Based on the review criteria, each of these pain intensity scales is brief, reliable, valid, and widely used. However, the NRS-11 was given the highest rating for use in NF clinical trials due to recommendations from pain experts and other consensus groups, its extensive use in research, strong psychometric data including sensitivity to change, and excellent feasibility in ages ≥ 8 years. CONCLUSIONS: The systematic review criteria and process are effective for identifying appropriate PRO measures and provide information utilized by the REiNS Collaboration to achieve consensus regarding PROs in NF clinical trials.
OBJECTIVES:Neurofibromatosis (NF) is a genetic disease with multiple clinical manifestations that can significantly impact quality of life (QOL). Clinical trials should include patient-reported outcomes (PROs) as endpoints to assess treatment effects on various aspects of QOL, but there is no consensus on the selection and use of such measures in NF. This article describes the PRO Working Group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Collaboration, its main goals, methods for identifying appropriate PRO measures for NF clinical trials, and recommendations for assessing pain intensity. METHODS: The REiNS PRO group selected core endpoint domains important to assess in NF. The members developed criteria to rate PRO measures, including patient characteristics, psychometric properties, and feasibility, and utilized a systematic process to evaluate PROs for NF clinical trials. Within the subdomain of pain intensity, the group reviewed the Numerical Rating Scale-11 (NRS-11), the Visual Analogue Scale, and the Faces Pain Scale-Revised using this process. RESULTS: Based on the review criteria, each of these pain intensity scales is brief, reliable, valid, and widely used. However, the NRS-11 was given the highest rating for use in NF clinical trials due to recommendations from pain experts and other consensus groups, its extensive use in research, strong psychometric data including sensitivity to change, and excellent feasibility in ages ≥ 8 years. CONCLUSIONS: The systematic review criteria and process are effective for identifying appropriate PRO measures and provide information utilized by the REiNS Collaboration to achieve consensus regarding PROs in NF clinical trials.
Authors: Anne Kari Knudsen; Cinzia Brunelli; Stein Kaasa; Giovanni Apolone; Oscar Corli; Mauro Montanari; Robin Fainsinger; Nina Aass; Peter Fayers; Augusto Caraceni; Pål Klepstad Journal: Eur J Pain Date: 2010-09-06 Impact factor: 3.931
Authors: Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch Journal: Pain Med Date: 2010-01-15 Impact factor: 3.750
Authors: Patrick J McGrath; Gary A Walco; Dennis C Turk; Robert H Dworkin; Mark T Brown; Karina Davidson; Christopher Eccleston; G Allen Finley; Kenneth Goldschneider; Lynne Haverkos; Sharon H Hertz; Gustaf Ljungman; Tonya Palermo; Bob A Rappaport; Thomas Rhodes; Neil Schechter; Jane Scott; Navil Sethna; Ola K Svensson; Jennifer Stinson; Carl L von Baeyer; Lynn Walker; Steven Weisman; Richard E White; Anne Zajicek; Lonnie Zeltzer Journal: J Pain Date: 2008-06-17 Impact factor: 5.820
Authors: Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher Journal: Neuro Oncol Date: 2014-10-14 Impact factor: 12.300
Authors: Robert A Avery; James A Katowitz; Michael J Fisher; Gena Heidary; Eva Dombi; Roger J Packer; Brigitte C Widemann Journal: Ophthalmology Date: 2016-11-03 Impact factor: 12.079
Authors: Staci Martin; Shawn Nelson Schmitt; Pamela L Wolters; Brittany Abel; Mary Anne Toledo-Tamula; Andrea Baldwin; Rikard K Wicksell; Melinda Merchant; Brigitte Widemann Journal: Pain Med Date: 2014-11-06 Impact factor: 3.750
Authors: John D Heiss; Aria Jamshidi; Smit Shah; Staci Martin; Pamela L Wolters; Davis P Argersinger; Katherine E Warren; Russell R Lonser Journal: J Neurosurg Pediatr Date: 2018-12-07 Impact factor: 2.375
Authors: Pamela L Wolters; Staci Martin; Vanessa L Merker; James H Tonsgard; Sondra E Solomon; Andrea Baldwin; Amanda L Bergner; Karin Walsh; Heather L Thompson; Kathy L Gardner; Cynthia M Hingtgen; Elizabeth Schorry; William N Dudley; Barbara Franklin Journal: Neurology Date: 2016-08-16 Impact factor: 9.910
Authors: Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich Journal: Neurology Date: 2016-08-16 Impact factor: 9.910
Authors: Frank D Buono; Matthew E Sprong; Erina Paul; Staci Martin; Kaitlyn Larkin; Amir Garakani Journal: Orphanet J Rare Dis Date: 2021-05-21 Impact factor: 4.123
Authors: Shivani Ahlawat; Asad Baig; Jaishri O Blakeley; Michael A Jacobs; Laura M Fayad Journal: J Magn Reson Imaging Date: 2016-03-17 Impact factor: 5.119